Surmodics, Inc.

    Surmodics, Inc.

    NNASDAQ:SRDX
    42.98
    USD
    0.00
    (0.00%)
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    3
    3.88
    4.21
    4.75
    5.49
    5.56
    6.18
    7.47
    7
    7.64
    7.18
    9.45
    8.91
    8.48
    Basic EPS, GAAP
    0.59
    1.05
    0.88
    0.92
    0.77
    0.3
    -0.34
    0.57
    0.08
    0.31
    -1.96
    -0.11
    -0.82
    -1.24
    Free Cash Flow per Basic Share
    0.89
    1.09
    1.17
    1.01
    1.31
    0.58
    1.52
    0.1
    0.76
    0.66
    -1.48
    0.54
    -0.23
    -0.25
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    4.42
    6.34
    6.94
    6.82
    7.6
    7.81
    7.47
    8.32
    8.3
    8.48
    6.43
    6.27
    5.4
    4.37
    Tangible Book Value per Share
    4.77
    5.68
    6.44
    6.22
    4.44
    4.84
    4.86
    6.13
    6.68
    4.17
    2.84
    3.62
    3.58
    3.04
    Basic Weighted Avg Shares
    17
    14
    14
    13
    13
    13
    13
    13
    14
    14
    14
    14
    14
    14
    Sales/Revenue/Turnover
    52
    56
    57
    62
    71
    73
    81
    100
    95
    105
    100
    133
    126
    121
    Operating Margin (%)
    31.47
    34.38
    32.34
    30.84
    30.18
    9.54
    -0.29
    7.19
    -1.32
    7.38
    -22.1
    4.23
    -4.48
    -10.22
    Depreciation Expense
    3
    3
    3
    3
    5
    6
    6
    7
    7
    8
    9
    9
    9
    8
    Net Income, GAAP
    10
    15
    12
    12
    10
    4
    -4
    8
    1
    4
    -27
    -2
    -12
    -18
    Effective Tax Rate (%)
    37.88
    28.39
    33.92
    34.5
    41.08
    44.18
    - -
    - -
    - -
    33.23
    - -
    161.76
    - -
    - -
    Profit Margin (%)
    19.7
    27.02
    20.95
    19.3
    13.99
    5.37
    -5.48
    7.59
    1.18
    4.03
    -27.29
    -1.16
    -9.15
    -14.59
    Working Capital
    33
    30
    51
    63
    48
    51
    46
    61
    68
    40
    26
    63
    61
    57
    LT Debt
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    3
    3
    4
    32
    32
    32
    Total Equity
    95
    94
    99
    92
    107
    112
    109
    123
    131
    140
    108
    120
    119
    111
    Return on Invested Capital (%)
    8.66
    14.64
    12.75
    13.12
    12.77
    3.57
    - -
    - -
    - -
    3.59
    - -
    -2.51
    - -
    - -
    Return on Capital (%)
    14.42
    18.02
    12.92
    13.03
    10.64
    3.9
    - -
    - -
    - -
    3.6
    - -
    -3.27
    - -
    - -
    Return on Common Equity (%)
    14.42
    18.02
    12.92
    13.03
    10.64
    3.9
    -4.43
    7.24
    1
    3.7
    -26.45
    -1.73
    -14.04
    -24.8

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'25
    Mar'25
    Jun'25
    ST Debt
    1
    1
    1
    LT Borrowings
    30
    30
    30
    LT Finance Leases
    2
    2
    2
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    14
    14
    14
    Market Capitalization
    562
    434
    423

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'25
    Mar'25
    Jun'25
    Total Current Assets
    72
    72
    76
    Cash, Cash Equivalents & STI
    30
    31
    33
    Accounts Receivable, Net
    13
    12
    13
    Inventories
    15
    16
    16
    Total Current Liabilities
    13
    14
    19
    Payables & Accruals
    7
    6
    10
    ST Debt
    1
    1
    1
    Deferred Revenue
    - -
    - -
    1

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    2.49%
    0.21%
    -0.84%
    Free Cash Flow
    10.9%
    16.79%
    -142.71%
    Net Income, GAAP
    -55.62%
    1.09%
    651.43%
    Sales/Revenue/Turnover
    8.82%
    5.69%
    -4.91%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    25
    27
    52
    28
    133
    2024
    31
    32
    30
    33
    126
    2025
    30
    28
    30
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.56
    -0.55
    0.52
    0.48
    -0.11
    2024
    -0.06
    0.02
    -0.53
    -0.24
    -0.82
    2025
    -0.26
    -0.36
    -0.37
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      Brokerages Set Surmodics, Inc. (NASDAQ:SRDX) Target Price at $43.00

    • defenseworld.net

      Groupe la Francaise Sells 33,700 Shares of Surmodics, Inc. $SRDX

    • businesswire.com

      Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today

    • benzinga.com

      Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge

    • businesswire.com

      Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR

    • businesswire.com

      Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

    • businesswire.com

      Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3

    • zacks.com

      SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts

    • zacks.com

      SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

    • zacks.com

      SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates

    • fool.com

      Surmodics (SRDX) Q3 EPS Turns Positive

    • businesswire.com

      Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

    • zacks.com

      Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

    • zacks.com

      SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

    • zacks.com

      SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say

    • zacks.com

      SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates

    • businesswire.com

      Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

    • businesswire.com

      Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

    • businesswire.com

      Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

    • zacks.com

      SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System